Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 664-672

  Annunziata, Christina M ^a   Walker, Amanda J ^a   Minasian, Lori ^a   Yu, Minshu ^a   Kotz, Herbert ^a   Wood, Bradford J ^b   Calvo, Katherine ^b   Choyke, Peter ^a   Kimm, Daniel ^a   Steinberg, Seth M ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 8; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL DISTENSION; ACNE; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRY SKIN; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOMAGNESEMIA; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RECURRENT CANCER; SIDE EFFECT; SKIN EXFOLIATION; TREATMENT OUTCOME; TUMOR BIOPSY; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, SEROUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; SIGNAL TRANSDUCTION; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 74549205168     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2308     Document Type: Article

References (28)

1. Fleming GF, Ronnett BM, Seidman J, Zaino RJ, Rubin SC. Epithelian ovarian cancer. In: Barakat RR, Markman M, Randall ME, editors. Principles and practices of gynecologic oncology. 5th ed. Baltimore: Lippincott, Williams and Wilkins; 2009, p. 763-836.
2. Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007;109:1323-30.
3. Palayekar MJ, Herzog TJ. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer 2008;18:879-90.
4. Annunziata CM, Azad NS, Hoskins ER, Kohn EC. Tumor invasion, angiogenesis and metastasis: biology and clinical application. In: Barakat RR, Markman M, Randall ME, editors. Principles and practices of gynecologic oncology. 5th ed. Baltimore: Lippincott, Williams and Wilkins; 2009, p. 71-84.
5. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007;25:2894-901.
6. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6.
7. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14.
8. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
9. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-7.
10. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407-15.
11. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009;27:2523-9.
12. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-9.
13. Espina V, Mehta AI, Winters ME, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003;3:2091-100.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
15. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15.
16. Golshayan AR, Brick AJ, Choueiri TK. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 2008;4:85-92.
17. Kiura K, Nakagawa K, Shinkai T, et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008;3:386-93.
18. Winters M, Dabir B, Yu M, Kohn EC. Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics 2007;7:4066-8.
19. Azad NS, Henning R, Yu M, et al. Translational proof of mechanism for sorafenib with bevacizumab: endpoint analysis and clinical activity. J Clin Oncol 2009;27:abstr 3574.
20. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-27.
21. Adamo V, Franchina T, Adamo B, et al. Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther 2009;8.
22. Lassus H, Sihto H, Leminen A, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 2006;84:671-81.
23. Stadlmann S, Gueth U, Reiser U, et al. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006;19:607-10.
24. Vermeij J, Teugels E, Bourgain C, et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008;8:3.
25. Schilder RJ, Pathak HB, Lokshin AE, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009;113:21-7.
26. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002;20:1161-3.
27. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007;107:118-23.
28. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71.